

Applicant : Klaus Cichutek et al.
Serial No. : Unassigned
Filed : Herewith
Page : 4

REMARKS


Amendments to the claims have been made to remove multiple dependency while conserving the claimed subject matter. In addition, applicants have amended the specification to include subheadings according to U.S. practice and to insert a Brief Description of the Drawings including a reference to sequence identification numbers.

Thus, no new matter has been introduced.

Attached is a marked-up version of the changes being made by the current amendment. Claims 1 to 10 are now pending. Applicants submit that all of the claims are now in condition for examination, which action is requested. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 11692-006US1.

Respectfully submitted,

Date: March 26, 2002


J. Peter Fasse
Reg. No. 32,983

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Applicant : Klaus Cichutek et al.
Serial No. : Unassigned
Filed : Herewith
Page : 5

Version with markings to show changes made

Prior to examination, please amend preliminarily the above-captioned patent application as follows:

In the Specification: (in the verified English translation)

At page 1, line 2, after the title, insert a new subheading and paragraph:

--Cross-Reference to Related Application--

This application claims priority from PCT/DE00/03444 filed on September 27, 2000, which claims priority from German Patent Application No. 199 46 1422, filed on September 27, 1999, both of which are incorporated herein by reference in their entirety.

--Field of the Invention--

At page 1, after the first paragraph, insert a new subheading:

--Background of the Invention--

At page 3, after the 2nd full paragraph (after line 6, insert

--Summary of the Invention--

At page 3, after the 8th full paragraph (after line 30), insert

--Brief Description of the Drawings--

Fig. 1 is a representation of a nucleic acid sequence of the invention, 7A5-scFv (SEQ ID NO: 1), and the amino acid sequence it encodes (SEQ ID NO: 6).

Fig. 2 is a representation of a nucleic acid sequence of the invention, K6-scFv (SEQ ID NO: 2), and the amino acid sequence it encodes (SEQ ID NO: 7).

Fig. 3 is a representation of a nucleic acid sequence of the invention, 7B2-scFv (SEQ ID NO: 3), and the amino acid sequence it encodes (SEQ ID NO: 8).

Fig. 4 is a representation of a nucleic acid sequence of the invention, 7E4-scFv (SEQ ID NO: 4), and the amino acid sequence it encodes (SEQ ID NO: 9).

Fig. 5 is a representation of a nucleic acid sequence of the invention, 6C3-scFv (SEQ ID NO: 5), and the amino acid sequence it encodes (SEQ ID NO: 10).

--Detailed Description--

At page 9, after the last paragraph, insert:

Applicant : Klaus Cichutek et al.
Serial No. : Unassigned
Filed : Herewith
Page : 6

--All references cited herein are incorporated by reference in their entirety.--

In the claims:

Claims 3, 4, 6, 7, 8, and 9 have been amended as follows:

--3. (Amended) The cell targeting vector according to [claims 1 or 2] claim 1 characterized in that the vector is T cell specific.

--4. (Amended) The cell targeting vector according to [claims 1 to 3] claim 1 characterized in that the vector is derived from SNV (Spleen Necrosis Virus).

--6. (Amended) The cell targeting vector according to [claims 1 to 5] claim 4 containing a therapeutic gene.

--7. (Amended) A pharmaceutical composition containing cell targeting vectors according [claims 1 to 6] claim 4.

--8. (Amended) The use of the cell targeting vectors according to [claims 1 to 6] claim 4 for gene therapy, vaccination therapy or diagnostics.

--9. (Amended) The use of the cell targeting vectors according to [claims 1 to 6] claim 3 for the therapy of T-cell-associated diseases.--

In the drawings:

The figures have been amended to include SEQ ID NOs as shown in red ink in the attached copies.